PAPER Caselli RJ, Dueck AC
SEARCH RESULTS
330059 RESULTS
PAPER Chiang GC, Insel PS, Tosun D, Schuff N, Truran-Sacrey D, Raptentsetsang ST, Jack CR, Aisen PS, Petersen RC, Weiner MW,
Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects.
Neurology. 2010 Nov 30;75(22):1976-81. PubMed: 20980669PAPER Vasileiou E, Montero RM, Turner CM, Vergoulas G
P2X(7) receptor at the heart of disease.
Hippokratia. 2010 Jul;14(3):155-63. PubMed: 20981163David Puchol Esparza
www.mhsynthesis.comValencia, Spain
PAPER Mohyeddin Bonab M, Yazdanbakhsh S, Lotfi J, Alimoghaddom K, Talebian F, Hooshmand F, Ghavamzadeh A, Nikbin B
Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study.
Iran J Immunol. 2007 Mar;4(1):50-7. PubMed: 17652844PAPER Kassis I, Grigoriadis N, Gowda-Kurkalli B, Mizrachi-Kol R, Ben-Hur T, Slavin S, Abramsky O, Karussis D
Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis.
Arch Neurol. 2008 Jun;65(6):753-61. PubMed: 18541795Lars Lannfelt on Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease.
COMMENT The potential of CSF α-synuclein as a biomarker for Parkinson’s disease has been investigated by Tokuda et al. The authors confirm their own previously reported findings of decreased total CSF α-synuclein in patients as compared to controls. What is novel
PAPER Baborie A, Griffiths TD, Jaros E, McKeith IG, Burn DJ, Richardson A, Ferrari R, Moreno J, Momeni P, Duplessis D, Pal P, Rollinson S, Pickering-Brown S, Thompson JC, Neary D, Snowden JS, Perry R, Mann DM
Pathological correlates of frontotemporal lobar degeneration in the elderly.
Acta Neuropathol. 2011 Mar;121(3):365-71. PubMed: 20978901PAPER Isacson O, Mendez I
Being too inclusive about synuclein inclusions.
Nat Med. 2010 Sep;16(9):960-1; author reply 961. PubMed: 20823871PAPER Alberio T, Bossi AM, Milli A, Parma E, Gariboldi MB, Tosi G, Lopiano L, Fasano M
Proteomic analysis of dopamine and α-synuclein interplay in a cellular model of Parkinson's disease pathogenesis.
FEBS J. 2010 Dec;277(23):4909-19. PubMed: 20977677PAPER Campbell GR, Watkins JD, Loret EP, Spector SA
Differential induction of rat neuronal excitotoxic cell death by human immunodeficiency virus type 1 clade B and C tat proteins.
AIDS Res Hum Retroviruses. 2011 Jun;27(6):647-54. PubMed: 20977378PAPER Cao S, Theodore S, Standaert DG
Fcγ receptors are required for NF-κB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson's disease.
Mol Neurodegener. 2010;5:42. PubMed: 20977765PAPER Lu QL, Yokota T, Takeda S, Garcia L, Muntoni F, Partridge T
The status of exon skipping as a therapeutic approach to duchenne muscular dystrophy.
Mol Ther. 2011 Jan;19(1):9-15. PubMed: 20978473An Oligomer Test for PD—Could One for AD Be Close Behind?
RESEARCH NEWS 2010-10-29 Research News Small, soluble oligomers of amyloid-β (Aβ) are now widely believed to be the most toxic form of the peptide. Could their presence in the cerebrospinal fluid (CSF) be an early sign of impending Alzheimer’s disease? That remains to be seen, un
Research Brief: Announcing ADNI2—Funding for Five More Years
RESEARCH NEWS 2010-10-29 Research News The much-awaited announcement that ADNI2 will go ahead was made 21 October 2010 by the National Institutes of Health. According to the NIH, the second phase of the Alzheimer’s Disease Neuroimaging Initiative will recruit an additional 550 vo
Current Filters
No filters selected